Home › Diffuse Large B-Cell Lymphoma › Texas › Austin
Diffuse Large B-Cell Lymphoma clinical trials in Austin, TX
5 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Austin (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- Texas Oncology - Central/South Texas ( Site 8006), Austin
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
- Texas Oncology - Central South, Austin
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
RecruitingObservational study
- Natera, Inc., Austin
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- St. David's South Austin Medical Center, Austin
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
RecruitingPhase 1
- NEXT Oncology, Austin, TX 78758
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Los Angeles, CA17 studies
- Houston, TX17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Portland, OR15 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Nashville, TN14 studies
- Dallas, TX13 studies
Other studies in Austin
- Non-Small Cell Lung Cancer30 studies
- Cancer (all types)21 studies
- Obesity20 studies
- Colorectal Cancer19 studies
- Metastatic Cancer19 studies
- Heart Failure18 studies
- Overweight18 studies
- Breast Cancer18 studies
- Ovarian Cancer17 studies
- Endometrial Cancer16 studies
- Prostate Cancer15 studies
- Depression14 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.